{"id":36126,"date":"2025-06-26T23:03:58","date_gmt":"2025-06-26T15:03:58","guid":{"rendered":"https:\/\/flcube.com\/?p=36126"},"modified":"2025-06-26T23:03:59","modified_gmt":"2025-06-26T15:03:59","slug":"fosun-pharmas-serplulimab-approved-for-es-sclc-in-the-uk-and-india","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36126","title":{"rendered":"Fosun Pharma&#8217;s Serplulimab Approved for ES-SCLC in the UK and India"},"content":{"rendered":"\n<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>) announced that its subsidiary Shanghai Henlius Biotech Inc.&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius&#8217; partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The approvals are based on results from the ASTRUM-005 study, conducted across 128 trial sites globally with 585 participants. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the final analysis of ASTRUM-005 demonstrated that with a median follow-up of 42.4 months, the 4-year overall survival (OS) rate in the serplulimab plus chemotherapy group reached 21.9% (95% CI: 17.6\u201326.6%). This confirms the long-term survival benefits of this immunotherapy regimen for ES-SCLC patients.<\/p>\n\n\n\n<p><strong>Global Impact<\/strong><br>Hansizhuang is the world&#8217;s first anti-PD-1 mAb approved for first-line SCLC treatment. It has been approved in nearly 40 countries and regions, including China, Indonesia, Singapore, and Germany, benefiting over 110,000 patients worldwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,159,270,893,862,18,15,892],"class_list":["post-36126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-fosun-pharmaceutical","tag-henlius-biotech","tag-hkg-2196","tag-hkg-2696","tag-pd-1-l1","tag-product-approvals","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma&#039;s Serplulimab Approved for ES-SCLC in the UK and India - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.&#039;s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius&#039; partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36126\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma&#039;s Serplulimab Approved for ES-SCLC in the UK and India\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.&#039;s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius&#039; partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36126\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T15:03:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-26T15:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma&#8217;s Serplulimab Approved for ES-SCLC in the UK and India\",\"datePublished\":\"2025-06-26T15:03:58+00:00\",\"dateModified\":\"2025-06-26T15:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605-1.webp\",\"keywords\":[\"Cancer\",\"Fosun Pharmaceutical\",\"Henlius Biotech\",\"HKG: 2196\",\"HKG: 2696\",\"PD-1\\\/L1\",\"Product approvals\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36126#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36126\",\"name\":\"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605-1.webp\",\"datePublished\":\"2025-06-26T15:03:58+00:00\",\"dateModified\":\"2025-06-26T15:03:59+00:00\",\"description\":\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.'s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius' partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36126\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma&#8217;s Serplulimab Approved for ES-SCLC in the UK and India\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.'s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius' partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36126","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India","og_description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.'s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius' partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.","og_url":"https:\/\/flcube.com\/?p=36126","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-26T15:03:58+00:00","article_modified_time":"2025-06-26T15:03:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36126#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36126"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma&#8217;s Serplulimab Approved for ES-SCLC in the UK and India","datePublished":"2025-06-26T15:03:58+00:00","dateModified":"2025-06-26T15:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36126"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","keywords":["Cancer","Fosun Pharmaceutical","Henlius Biotech","HKG: 2196","HKG: 2696","PD-1\/L1","Product approvals","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36126#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36126","url":"https:\/\/flcube.com\/?p=36126","name":"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36126#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","datePublished":"2025-06-26T15:03:58+00:00","dateModified":"2025-06-26T15:03:59+00:00","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc.'s (HKG: 2696) self-developed anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab, marketed as Hetronifly in Europe) has received approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Indian Central Drugs Standard Control Organization (CDSCO) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product will be commercialized in these regions by Henlius' partner Intas Pharmaceuticals and its subsidiary Accord Healthcare under the brand name Hetronifly.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36126#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36126"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36126#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","width":1080,"height":608,"caption":"Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma&#8217;s Serplulimab Approved for ES-SCLC in the UK and India"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36126"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36126\/revisions"}],"predecessor-version":[{"id":36129,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36126\/revisions\/36129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36128"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}